Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression — A retrospective study | Synapse
March 3, 2026
Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression — A retrospective study
Key Points
Patients experienced significant relief from treatment-resistant depression symptoms with a combination of esketamine and dexmedetomidine.
The study documented a notable improvement of depression scores over a defined follow-up period, highlighting efficacy.
Retrospective analysis examined historical patient data from those who received the multimodal intervention successfully.
These findings support the potential of combined therapies in managing challenging depression cases, warranting further exploration.